Brain Cancer | Tumor

CURE’s brain cancer page features the latest cancer news and updates on brain cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in brain cancer.

IGV-001 Shows Longer Survival for Newly Diagnosed Glioblastoma

December 3rd 2025, 4:00pm

Article

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

Voranigo is Safe and Tolerable in High-Grade IDH-Mutant Gliomas

November 24th 2025, 5:58pm

Article

Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.

Imbruvica Plus Drug Combo Shows Strong Responses in Newly Diagnosed PCNSL

November 24th 2025, 4:05pm

Article

Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

Eflornithine Plus Gleostine Improves Progression, Survival In Some With Astrocytoma

November 23rd 2025, 2:00pm

Article

Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.

B7-H3 CAR T-Cell Therapy Shows Acceptable Safety in Recurrent Glioblastoma

November 22nd 2025, 3:55pm

Article

Intraventricular B7-H3 CAR T-cell therapy was well tolerated up to 1 x 10⁷ cells per infusion and showed early signs of activity in recurrent glioblastoma.

Voranigo Plus Temodar Found to Be Safe in Patients With IDH1/2+ Glioma

November 22nd 2025, 3:45pm

Article

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations.

Gomekli Shows Early Activity in Pediatric Low Grade Glioma

November 22nd 2025, 2:10pm

Article

Early data from the SJ901 study show Gomekli generates responses with manageable side effects in children and young adults with low grade glioma.

Early Real-World Uptake of Voranigo in Patients With IDH-Mutant Glioma

November 21st 2025, 10:55pm

Article

Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.

Effective Early Treatments Needed in Glioma, Real-World Data Finds

November 21st 2025, 10:30pm

Article

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Finding Gratitude and Love for Cancer Patients and Caregivers

November 19th 2025, 10:00pm

Article

I reflect on my brain tumor journey, sharing how gratitude, love and connection with my parents and others strengthened me through difficult times.